You are here

Positive Results Reported for Breast Cancer Vaccine

Treatment targets cancer-associated antigen mammaglobin-A

A DNA vaccine targeting mammaglobin-A, a breast cancer-associated antigen, was shown to be safe and effective in eliciting immune responses in women with metastatic breast cancer, according to a study published in Clinical Cancer Research.

“This study builds on extensive studies of mammaglobin-A immunobiology and confirms that it is an attractive target for immune intervention in breast cancer patients,” said author William E. Gillanders, MD.

“Mammaglobin-A is an excellent target for breast cancer vaccine therapy because it is specific to breast cancer tissue, and it is over-expressed in most breast cancers, including noninvasive, invasive, or metastatic breast cancers,” Gillanders said. “These unique properties mean that a mammaglobin-A vaccine could be therapeutic, given after breast cancer has developed to treat or prevent disease recurrence, or preventive, given to patients before they are diagnosed with breast cancer.”

Gillanders and his colleagues treated 14 patients with metastatic breast cancer with the mammaglobin-A vaccine. The patients reported only minor adverse effects, such as injection-site reactions or temporary fevers.

Using flow cytometry, the researchers found that the frequency of mammaglobin-A–specific CD8 T cells at baseline increased more than fourfold and after vaccination, indicating a robust immune response.

“Measuring mammaglobin-A–specific CD8 T cells is one way to measure vaccine efficacy,” Gillanders explained. “Although CD8 T cells are only one component of the immune response, they are arguably the most important component.”

The analysis also showed that the patients treated with the vaccine had prolonged progression-free survival compared with those who did not receive the vaccine; however, the study was not designed to compare survival among these groups.

“I predict that this vaccine and similar vaccines could have the greatest clinical impact in patients who have completed standard treatment regimens, such as chemotherapy, surgery, or radiation, to minimize the risk of recurrence,” Gillanders said. “That would help to improve the overall success rate associated with current treatment paradigms.”

Sources: AACR; December 1, 2014; and Clinical Cancer Research; December 1, 2014.

Recent Headlines

First New Medication for Seizure Clusters in More Than Two Decades
Novel, Low-cost Device Highly Accurate at Screening Newborn Jaundice
Mode Delivers Antivirals Safely, Cheaply to Remote Regions
First Devices Cleared for Diagnostic Testing Via Throat, Rectum Specimens
Averts Disease Worsening, Reduces Potential for Blindness
Risk May Remain for 6 Months After Treatment
FDA Removes Boxed Warning With Drug’s Fifth Approval
Overeager Use of Recommendations Creates Problems
Artificial Intelligence Enables Platform to Detect Amyloid PET Status